![Sabine Oertelt](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/sex-and-gender-sensitive-medicine-are-we-ready-to-switch-paradigm/8734420-3-eng-GB/sex-and-gender-sensitive-medicine-are-we-ready-to-switch-paradigm_i770.jpg)
Sex and gender-sensitive medicine: are we ready to switch paradigm?
Examining sex- and gender-related differences may potentially be the new frontier in the era of precision medicine to tailor cancer treatments in men and women.
Examining sex- and gender-related differences may potentially be the new frontier in the era of precision medicine to tailor cancer treatments in men and women.
Results from ASCEND-7 trial confirms the place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer and active brain metastases
2019 marks the 30th Anniversary of the ESMO Fellowship Programme, a programme that has provided many young oncologists valuable educational opportunities, shaped professional lives and enhanced careers
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.